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Abstract: Leber’s hereditary optic neuropathy (LHON) is a mitochondrial disorder leading to severe visual impairment or 
even blindness by death of retinal ganglion cells (RGCs). The primary cause of the disease is usually a mutation of the mi-
tochondrial genome (mtDNA) causing a single amino acid exchange in one of the mtDNA-encoded subunits of 
NADH:ubiquinone oxidoreductase, the first complex of the electron transport chain. It was thus obvious to accuse neu-
ronal energy depletion as the most probable mediator of neuronal death. The group of Valerio Carelli and other authors 
have nicely shown that energy depletion shapes the cell fate in a LHON cybrid cell model. However, the cybrids used 
were osteosarcoma cells, which do not fully model neuronal energy metabolism. Although complex I mutations may 
cause oxidative stress, a potential pathogenetic role of the latter was less taken into focus. The hypothesis of bioenergetic 
failure does not provide a simple explanation for the relatively late disease onset and for the incomplete penetrance, which 
differs remarkably between genders. It is assumed that other genetic and environmental factors are needed in addition to 
the ‘primary LHON mutations’ to elicit RGC death. Relevant nuclear modifier genes have not been identified so far. The 
review discusses the unresolved problems of a pathogenetic hypothesis based on ATP decline and/or ROS-induced apop-
tosis in RGCs. 
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1. INTRODUCTION 
  The first description of a patient suffering from Leber’s 
Hereditary Optic Neuropathy (LHON) dates back more than 
150 years to a report of von Graefe [1], but the disease was 
first recognized as a distinctive clinical entity by the German 
ophthalmologist Theodor Leber in 1871 [2]. Due to a strong 
gender bias, favouring the outbreak of this inherited optic 
neuropathy in young men, it had been considered to be X-
linked for a long time. Hundred years after Leber’s report, it 
was recognized that the mode of inheritance was maternal 
and thus compatible with mutations in the mitochondrial 
genome, the mtDNA [3]. In 1988, the first LHON-associated 
mtDNA mutation was discovered by Douglas C. Wallace 
and colleagues in the ND4 gene (NADH dehydrogenase 4), 
coding for a polypeptide of complex I of the electron trans-
port chain (ETC) [4]. Since that time, five other complex I 
mutations have been confirmed to be clearly pathogenic in 
LHON (www.mitomap.org), a total of three mutations in 
polypeptides ND1 (G3460A) [5], ND4 (G11778A) [4] and 
ND6 (T14484C) [6] being responsible for 90-95% of all 
cases. A large number of other mtDNA mutations are sus-
pected to cause LHON, to facilitate disease outbreak or mod-
ify the phenotype. However, it is a striking feature of the 
disease that all confirmed pathogenic mutations cause amino 
acid exchanges in complex I (NADH:ubiquinone oxi-
doreductase, E.C.1.6.5.3). 
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  By a mechanism, which is yet not fully understood, these 
substitutions cause an acute oder sub-acute loss of retinal 
ganglion cells (RGCs) and their axons, comprising the optic 
nerve, leading to blindness or at least severe central vision 
loss. RGC loss occurs in about 50% of male and only 10-
15% of female mutation carriers, but penetrance may vary 
even among pedigrees harbouring the same mutation. In con-
trast to several other mitochondrial disorders caused by de-
fects of the bioenergetic machinery, LHON is often regarded 
as a non-syndromic disease, because RGC loss is the only 
clinically relevant phenotype in most patients. Only rarely 
other phenotypes have been ascribed to the same mutations 
besides optic atrophy, such as dystonia, multiple-sclerosis-
like illness or cerebellar ataxia [7-12]. No other major neu-
ronal losses have been detected in affected retinae, although 
e.g. the requirement of photoreceptor cells for ATP genera-
tion by oxidative phosphorylation (OXPHOS) is very high. 
The enigmatic selectivity of the phenotype is even more as-
tonishing, if one keeps in mind that the frequent ND4 muta-
tion often occurs in a homoplasmic state in blood and other 
tissues analyzed, comprising 100% of total mtDNA. There-
fore, the amino acid substitutions seem to evoke a relatively 
mild biochemical defect in complex I, which leads to cell 
death only in RGCs. These cells exhibit a selective vulner-
ability for reasons, which are not fully understood.  
  The disease can occur at any age, although most often 
young men in their second or third decade of life are af-
fected. Usually both eyes are involved, but with a time delay 
of some monthes between them, which can be even longer 
than a decade in some cases [13]. Often the disease pro-
gresses rapidly leading to severe visual loss with only little 
probability of partial visual recovery [14]. A cecocentral 
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vision. Ophthalmologic findings are variable and major fun-
dus changes may even be absent in the acute phase of the 
disease. Early ophthalmologic changes can include hyper-
hemic optic discs, disc pseudo-oedema and microangiopathy 
[15]. The disease finally leads to optic disc atrophy.  
  Altough the primary causes of LHON have been identi-
fied in the last two decades to be amino acid substitutions in 
complex I polypeptides, this has not yet lead to a satisfying 
explanation of the pathophysiological mechanisms. The fol-
lowing two issues belong to the most disturbing enigmas of 
the pathomechanism: 
A)  If bioenergetic failure should be the main conse-
quence of the mutations, why are other OXPHOS-
dependent retinal cells unaffected, such as photore-
ceptors ? Oxidative ATP generation relies on a func-
tional ETC, which generates an electrochemical gra-
dient across the inner mitochondrial membrane, and a 
functional ATP-synthetase, utilizing this gradient. 
Missense mutations (np8993) of the mtDNA-encoded 
ATP-synthetase subunit 6 (OXPHOS complex V) can 
cause a broader spectrum of retinal and brain dys-
functions and eventually cause lethal Leigh disease, 
characterized by brain necrosis (www.mitomap.org). 
These amino acid exchanges do not mainly induce 
RGC loss. What explains the selective vulnerability 
of RGCs towards the complex I mutations ?  
B)  Why are male mutation carriers at a higher risk to 
develop LHON and which other factors trigger the 
disease ?  
2. VARIABLE BIOCHEMICAL PHENOTYPE OF 
PRIMARY LHON MUTATIONS 
  Oxygraphic measurements of total oxygen consumption 
of whole cells, of mitochondrial respiration with complex I 
substrates, and assays of the NADH:ubiquinone oxidoreduc-
tase enzyme activity have been performed by many authors 
to characterize the biochemical phenotype of the three most 
common primary LHON mutations. Because they occurred 
in a homoplasmic state or at least accounted for a high per-
centage of total mtDNA in blood platelets and lymphocytes, 
these cells were often exploited as a starting material. Be-
sides these ‘natural’ cell sources, Eppstein- Barr virus (EBV) 
transformed lymphoblasts were sometimes prefered to obtain 
larger amounts of starting material for biochemical analysis, 
or ‘transmitochondrial cybrids’ (see below) were con-
structed.  
  Among the three common mutations, only G3460A 
(ND1) was invariably described to cause a considerable and 
significant decline of NADH:ubiquinone oxidoreductase 
activity [16-20]. In contrast to these results, no significant 
decrease of enzyme activity was observed in several studies 
analyzing the mutations in ND6 [21] or ND4 [16, 22], the 
latter accounting for most LHON cases. In other reports a 
minor decline of complex I activity was described in cells 
harbouring the ND4 mutation [20], or became only visible, if 
the statistical analysis was restricted to non-smokers [18]. 
This indicated that the influence of environmental factors 
may be large enough to mask the moderate effect of the mu-
tation. Cell culture studies with cybrids revealed at least a 
decreased growth rate of mutated cells together with lower 
oxygen consumption [13].  
  A decline of mitochondrial respiration with complex I 
substrates (malate + pyruvat, malate + glutamate) was con-
firmed in assays of isolated mitochondria derived from EBV-
transformed lymphoblasts and cybrids carrying any of the 
three common mutations [20]. These results, together with 
an aberrant behaviour of mutant mitochondria towards com-
plex I inhibitors [19] clearly demonstrated a dysfunction of 
complex I in all cases. According to the heterogeneous en-
zymatic data and to the location of the amino acid substitu-
tions in three different polypeptides, a precisely identical 
mechanism of the three common mutations was not likely. 
Nevertheless it was reasonable to assume a disturbed energy 
conserving function of complex I as the common result. 
3. THE CYBRID MODEL 
  Since the discovery of the primary LHON mutations, the 
so called transmitochondrial cytoplasmic hybrid (‘cybrid’) 
model has been extensively used to characterize the bio-
chemical phenotypes of mutations, independent of the nu-
clear background. To achieve this goal, Michael King and 
Guiseppe Attardi introduced a technique to deplete 
143B.TK
- osteosarcoma cells of their mitochondrial DNA by 
sublethal concentrations of the DNA-intercalating dye ethid-
ium bromide, and to repopulate these so called rho-0 cells 
with foreign mtDNA from enucleated ‘mtDNA donors’ [23]. 
For this purpose, the osteosarcoma cells had been exposed to 
ethidium bromide for a long time, until no residual mtDNA 
was detectable. Two viable rho-0 clones were obtained in 
this way, which were found to rely exclusively on glycolysis 
for ATP generation due to lacking OXPHOS. Moreover, the 
cells had developed pyrimidine auxotrophy due to the defi-
ciency of the ETC-dependent dihydroorotate dehydrogenase 
[24]. Cell proliferation was strongly inhibited in the absence 
of uridine. After fusion of these cells with enucleated ‘cyto-
plasts’ of a cell line chosen to be the ‘mtDNA donor’, the 
generated cybrids were successfully repopulated with func-
tional mitochondria and able to grow independent of uridine 
supplementation. The small percentage of successful viable 
fusions could thus be selected by a growth medium lacking 
uridine. If cytoplasts derived from LHON patients and con-
trols are used as ‘mtDNA donors’ in this model, the bio-
chemical alterations found in the resulting cybrids solely 
reflect the different mtDNA sequences.  
  One of the original rho-0 clones obtained by King and 
Attardi (rho-0 206) has been distributed to several laborato-
ries and many major LHON cybrid studies have thus been 
performed on the basis of a single 143B.TK
- rho-0 line [13, 
22, 25-28]. These studies include importat work, which 
demonstrated a reduced rate of ATP synthesis and reduced 
ATP content in LHON cybrids under metabolic stress condi-
tions (see below). It may be noteworthy that an additional 
risk can be seen in this restriction, besides the generally rec-
ognized problem of exploiting tumor cells as models for a 
defective neuronal energy metabolism. Techniques were 
developed to exploit other tumor cell lines for cybrid con-
struction, such as teratoma or neuroblastoma lines, and to 
exploit blood platelets as ‘mtDNA donor cells’, which do not 
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were performed with cybrids derived from the NTera-2 
(NT2) teratoma line [29-31].  
3.1. LHON Mutations Confer ATP Decline and Sensitize 
Cybrids to Apoptosis  
  Due to the fact that RGC loss in LHON is painless and 
occurs without any signs of inflammation, an apoptotic cell 
death was suggested [32, 33]. Moreover, this mode of cell 
death was compatible with mitochondrial dysfunction. Dan-
ielson and colleagues reported enhanced apoptosis following 
FAS stimulation of cybrids bearing the ND1 or ND4 muta-
tions, as compared to wild-type cybrids [25]. The mode of 
cell death was apoptotic by several criteria, including activa-
tion of caspase-3, increased DNA fragmentation (laddering) 
and enhanced annexin-V staining. Since the FAS-ligand is 
expressed in the retina, the authors suggested death receptor-
mediated apoptosis to play a role in vivo. The authors pro-
posed an enhanced opening propability of the mitochondrial 
permeability transition pore (PTP) due to complex I dysfunc-
tion as a potential mechanism for the enhanced sensitivity 
towards apoptotic stimulation, since ETC complex I had 
already been associated earlier with PTP function [34]. Al-
though receptor-mediated apoptosis does not necessarily 
involve mitochondria, death receptor stimulation can be in-
terconnected with these organelles via proteins of the Bcl2 
(B-cell lymphoma 2) family. Fas-sensitivity may thus be en-
hanced in cells being sensitized to prolonged PTP opening.  
  Shortly thereafter, Ghelli and colleagues demonstrated 
that cybrids with either one of the three most common pri-
mary LHON mutations undergo apoptotic cell death, as 
judged by chromatin staining and DNA laddering, when ex-
posed to media, in which 20 mM glucose had been replaced 
by 5 mM galactose [26]. This effect was not observed within 
comparable time intervals in control cybrids. Galactose me-
dia were thought to facilitate the detection of OXPHOS defi-
ciency, which may be masked by a rapidly running glyco-
lytic pathway in tumor cells. Galactose, which is more 
slowly activated for glycolysis, was thought to render the 
cells more dependent on mitochondrial ATP generation, 
since only OXPHOS can satisfy the energy demand under 
conditions of a strongly restricted glycolytic activity. In OX-
PHOS-deficient cells ATP decline and eventually cell death 
should occur in galactose medium. The results of Ghelli and 
colleagues were thus interpreted in terms of enhanced apop-
totic sensitivity of LHON cybrids due to bioenergetic failure, 
which cannot be observed in normal cell culture media due 
to compensation by glycolysis. These results are in accor-
dance with apoptosis-induction in immortalized RGCs (cell 
line RGC-5) due to severe energy decline elicited by glucose 
deprivation [35].  
  Although galactose media were successfully used later in 
several important LHON studies, one critical remark should 
be considered. Galactose medium (5 mM) had been de-
scribed in 1992 as a tool for a first screening of cells from 
patients suspected to suffer from mitochondrial disorders. 
Cells with several types of mutations affecting OXPHOS 
died in this medium, while cells with other types of OX-
PHOS-relevant mutations survived. Among the latter were 
LHON cells [36]. This suggests that the interpretation of all 
galactose effects in osteosarcoma cybrids, e.g. apoptosis in-
duction, solely in terms of bioenergetic failure may be pre-
mature.  
  Nevertheless, ATP decline (nmol ATP / mg cellular pro-
tein) occurs in 143B.TK
- LHON cybrids in DMEM with 5 
mM galactose [27, 37]. This observation was made for cy-
brids containing any of the three mutations in polypeptides 
ND1, ND4 or ND6 (Fig. 1), but did not occur in the parental 
cell line or control cybrids. The LHON cells rapidly died. In 
the study of Zanna and colleagues [27], the mode of cell 
death was analyzed in more detail. It was again demonstrated 
to be apoptotic, because cytochrome c, apoptosis inducing 
factor (AIF) and endonuclease G (endo-G) were released 
from the mitochondria into the cytosol. Because no caspase-
activation was observed in this model, it was hypothesized 
that the concomitant dramatic decline in available ATP pre-
vented the aggregation of a functional apoptosome, which 
requires ATP, while AIF and endo-G release are sufficient to 
execute apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). ATP content in 142B.TK
- cybrid cells, harbouring the three 
most common primary LHON mutations, and in the parental cell 
line were determined in triplicate after various incubation periods in 
galactose-medium. Modified according to [37]. 
  Due to the incompletely understood role of galactose in 
generating metabolic stress, a direct proof was missing that 
the LHON mutations per se lead to an impaired ATP synthe-
sis rate with complex I substrates. This was finally proven by 
Baracca and colleagues in 2005 [28], who detected the most 
severe impairment of the ATP synthesis rate, a 90% de-
crease, in cells bearing the G3460A mutation (ND1), which 
had been most consistently reported to mediate a severe de-
crease of NADH:ubiquinone oxidoreductase activity.  
3.2. Oxidative Stress, Calcium and Permeability Transi-
tion 
  Reactive oxygen species (ROS) are suspected to partici-
pate in the pathophysiology of several neurodegenerative 
diseases, such as Parkinsons Disease, Amyotrophic Lateral 
Sclerosis and Alzheimer’s Disease, and in the pathophysiol-
ogy of mitochondrial disorders. Because ETC complex I is 
known to be a major ROS source, LHON mutations may 
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increase ROS generation and thus enhance apoptotic suscep-
tibility, eventually by favouring PTP opening. Calcium de-
regulation is another important factor, which is discussed in 
LHON. For example, dysfunctional mitochondria may be 
more prone to damage by increased cytoplasmic calcium 
concentrations. Calcium overload is well known to cause 
neuronal damage and plays a role for the opening probability 
of the PTP.  
 Accordingly, there were good reasons to analyse the im-
pact of externally applied oxidants and calcium on LHON 
cybrids. Already in 1997, Wong and Cortopassi described an 
enhanced sensitivity of 143B.TK
- LHON cybrids towards 
hydrogen peroxide, using a simple cell viability assay [38]. 
Interestingly, this sensitivity could be partially reversed by 
calcium withdrawal from the medium and by cyclosporine A 
(CsA), a known PTP inhibitor. These results pointed to a 
participation of oxidative stress and an altered PTP function 
in LHON. In a later study, the authors created NT2 teratoma 
cybrids, in order to generate a more realistic model, allowing 
neuronal differentiation by retinoic acid [29]. Only in the 
differentiated state, a significantly enhanced ROS production 
was observed in all LHON cells (mutations G3460A and 
G11778A) as compared to controls. This result may be inter-
preted in terms of elevated OXPHOS-dependency of the 
differentiated neurons in contrast to proliferating tumor cells, 
allowing to measure enhanced ROS-production by the mu-
tated complex I. At least it demonstrated a role of the ‘neu-
ronal environment’. Using confocal real-time imaging tech-
niques, our collaborator F. Haroon and colleagues observed a 
slightly increased ROS level in the same LHON cybrids 
(G11778A) even without differentiation [30], which became 
much more pronounced following addition of an external 
oxidant (Fig. 2). The cybrids had been kindly provided by G. 
Cortopassi and A. Wong (University of California, Davis, 
CA).  
  In the same study, the authors investigated calcium de-
regulation, following a cytoplasmic calcium rise induced by 
acetylcholin and the inhibitor thapsigargin, which blocks 
calcium uptake into the endoplasmic reticulum. The cells 
were cultured in a temperature controlled chamber, which 
could be perfused with medium. Fluorescent real-time imag-
ing could be performed with an inverted laser scanning mi-
croscope. The technique allowed to add or wash out acetyl-
cholin and thapsigargin rapidly and to determine cytoplasmic 
calcium concentrations using cells loaded with a calcium-
sensitive fluorescent dye (Fura PE3-AM). An incomplete 
reconstitution of normal cytosolic calcium levels, when the 
stimulated cells were washed with buffer, was observed se-
lectively in LHON cybrids. This deregulation could largely 
be abolished by CsA, indicating a role of the mitochondrial 
PTP. The results suggested that mitochondria with mutated 
complex I have a lower ability to sequester calcium, because 
lower calcium loads are sufficient to elicit prolonged PTP 
opening (permeability transition). This could mean that nor-
mal cytoplasmic calcium concentrations may become toxic, 
if they occur in mutated neurons.  
  The complex I inhibitor rotenone depolarizes the mito-
chondrial membrane potential in cybrids. Using cells har-
bouring the T14484C mutation (ND6) and a secondary ND6 
mutation, it was recently shown that the divalent cation 
chelator BAPTA-TM, the vitamin E derivative Trolox and 
CsA were all able to abolish a rotenone-induced collapse of 
, which occurred in the mutant cells, but not in the paren-
tal wild-type cells after identical rotenone-treatment [39]. In 
addition, CsA was shown to partially abolish the depolariza-
tion caused by a replacement of the sugar glucose in the cell 
culture medium by galactose. The protective effects of CsA, 
Ca
2+ withdrawal (chelators) and antioxidants in the mutant 
cells prompted the authors to propose a hypothesis, in which 
permeability transition (PT) causes the rotenone-induced 
collapse of  in mutant cells, instead of being a result of it 
(for details see Fig. 3). Porcelli and colleagues ascribed this 
central role to the PTP, since the pore is trigered by  de-
cline and the threshold voltage depends on Ca
2+ concentra-
tion and ROS level.  
  The authors hypothesized that the complex I mutations 
may shift the voltage threshold for PTP opening towards the 
resting level, due to Ca
2+ deregulation and enhanced ROS 
generation. In healthy control cells, an initial rotenone-
induced decrease of  may be compensated on the expense 
of ATP, consumed by a reverse action of the F0/F1-ATP-
synthetase. In cybrids with mutant complex I and lower volt-
age threshold for PT, the pore may open immediately after 
rotenone treatment, before the reversed ATP-synthetase has 
any chance to normalize . This compensatory process 
cannot occur anymore, once the inner mitochondrial mem-
brane is permeabilized. Although there may remain doubts 
regarding this interpretation, the experiments again sup-
ported a role for oxidative stress, calcium and permeability 
transition in LHON.  
 
 
 
 
 
 
 
 
 
 
Fig. (2). Representative graphs of DFF fluorescence visualizing 
intracellular ROS levels of NTera-2 (NT2) deruived LHON cy-
brids, carrying either the ND4 mutation at np11778 or normal 
mtDNA, over a period of ten minutes, using confocal real-time-
imaging. After 100 seconds, H2O2 (100 M) was added in order to 
saturate antioxidant defence mechanisms of the cybrids.  
It can be seen that Vit C (100 M vitamin C) completely abolished 
the enhanced ROS levels of LHON cybrids. The PTP inhibitor CsA 
(cyclosporine A, 3 M) was used in this set of experiments, since 
CsA had been found to partially inhibit calcium deregulation and 
cell death following stimulation of the LHON cybrids with an in-
hibitor of the smoth endoplasmic reticulum ATPase (thapsigargin). 
Since CsA did not influence DFF fluorescence, the measured ROS 
levels were not associated with permeability transition, which may 
occur after H2O2 addition. Modified according to [30].  
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Fig. (3). Schematic drawing outlining the hypothesis that LHON 
mutations in complex I (mut) may cause a shift in the potential, 
which is required for permeability transition (PT), towards the nor-
mal , creating an abnormally low voltage threshold for PT [39]. 
The shift is assumed to be mediated by Ca
2+ deregulation and en-
hanced production of reactive oxygen species (ROS) in the mutant 
mitochondria, which both alter the permeability transition pore. As 
a consequence of this lowered threshold, a small rotenone-induced 
 decline may immediately elicit PT leading to a complete and 
irreversible collapse of  and oxidative phosphorylation. In cells 
with wild-type complex I (wt), the same rotenone-induced  de-
cline may not be sufficient for opening of the pore. Reconstitution 
of a normal  may occur by a reversed action of the F0/F1-ATP-
synthethase on the expense of glycolytic ATP (compensation).  
  A potential role of oxidative stress was further underlined 
by some studies analyzing antioxidant defences. In the 
143B.TK
- cybrid model, any of the three common mutations 
led to a fast increase in the oxidized form of glutathione 
(GSSG), if the cells were grown in galactose medium [40]. 
This was interpreted in terms of oxidative stress of mutant 
cells in a medium, in which they strongly rely on OXPHOS 
to satisfy their ATP demand. In the same cybrids cultured in 
normal DMEM, the oxidant tert-butyl hydroperoxide could 
induce apoptosis, but cells were protected by external ad-
ministration of the antioxidant glutathione [41]. In our labo-
ratory, NT2-derived LHON cybrids with the G11778A muta-
tion, kindly provided by A. Wong and G. Cortopassi, had 
been found to contain decreased levels of total glutathione 
per mg cellular protein as compared to controls, if the cells 
had been treated shortly with the differentiating agent reti-
noic acid [31] in order to enhance their OXPHOS-
dependency.  
  Moreover, Qi and colleagues infected 143B.TK
- cybrids 
carrying the G11778A mutation with an adeno-associated 
viral vector (AAV) inducing mitochondrial overexpression 
of superoxide dismutase 2 (SOD2) in order to protect the 
LHON cells against enhanced superoxide production by the 
mutant complex I. The latter is known to deliver superoxide 
to the mitochondrial matrix compartment. Superoxide pro-
duction decreased, as concluded from dihydroethidium fluo-
rescence. The apoptotic index was reduced and short term 
cell survival enhanced [42]. The general ability of oxidative 
stress to induce apoptosis in RGCs has also been demon-
strated in the RGC-5 cell line [43].  
3.3. Limitations of Data Generated in Cybrid Models  
  While an extremely high OXPHOS activity may be re-
quired especially in the unmyelinated axon sections of RGCs 
(see below), all cybrid models rely on the polyethylene gly-
col mediated fusion between cytoplasts or platelets (mtDNA 
donors) and rho-0 cells. The latter grow without OXPHOS 
and tumor cells in general use glycolysis besides OXPHOS 
even under aerobic conditions for their ATP supply. This 
means that artificial conditions, such as galactose medium, 
had to be found to simulate a high utilization of the mutant 
complex I. Cybrids prepared from NT2 teratoma lines were 
used as a model, which better reflects the neuronal pheno-
type, because NT2 cells can be differentiated by controlled 
cell density, medium conditions and retinoic acid. However, 
not all NT2-derived cybrids were responsive to the differen-
tiating conditions. In responsive lines the achievable yield of 
terminally differentiated LHON-neurons was low [29], thus 
restricting the experiments to microscopic observations and 
other techniques not requiring larger amounts of cells.  
  Moreover, tumor cell lines are often populations of ge-
netically heterogeneous cells with non-identical sets of 
chromosomes and multiple chromosomal imbalances, visible 
on the molecular genetic level. Because the generation of 
rho-0 cells and cybrids represents a clonal selection from a 
tumor cell line, any clone will contain some nuclear genetic 
features, which were randomly picked up from the original 
cell population. In addition, genetic instability of the fusion 
products may lead to further diversification. The ideal model 
of identical nuclear background, allowing the isolation of 
mtDNA-mediated biochemical phenotypes, is not completely 
realized, as illustrated by occasional chromosomal losses and 
losses of heteroplasmy (LOH) in microsatellite markers [31]. 
Since a long term application of ethidium bromide was one 
of the most commonly used methods for mtDNA depletion, 
one may also ask, whether a large burden of chromosomal 
gene mutations is introduced into rho-0 cells. Besides differ-
ences on the DNA level, the transcriptome is strongly af-
fected by the processes of mtDNA-depletion and cell fusion 
(cybridization), as clearly demonstrated by Danielson and 
colleagues, using a microarray approach [44]. As already 
suggested by other authors, the use of only a single cybrid 
clone with a particular mutation within a study bears risks. 
Clones derived from the same mtDNA donor sometimes 
vary remarkably in complex I activity. However, the strong-
est restriction of the existing literature data can be recog-
nized in the use of a single rho-0 cell line for the central 
studies related to OXPHOS and apoptosis.  
4. MORE THAN BIOENERGETIC FAILURE? 
  As already stated above, a pathophysiologic hypothesis 
based solely on a decreased OXPHOS capacity of mutated 
RGCs is not completely satisfactory.  
  Although there is as yet no precise hypothesis clearly 
addressing the issue of cell-type specificity, some interesting 
ideas have been formulated, which discuss potential contri-
butions of the micromorphologic architecture of retinal nerve 
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fiber layer (RNFL), optic nerve head and optic nerve. These 
hypotheses rely on the dramatic polarity of RGCs, with their 
cell bodies sending out axons of about 5 cm length to con-
nect the neural retina with the brain [45]. This polarity in-
cludes an unequal distribution of mitochondria along the 
path of the axons and the fact that the axon sections within 
the RNFL are not wrapped into myelin sheets.  
  The latter aspect was discussed by several authors as an 
explanation for the extremely high energy demands of this 
first axon section. The impossibility of saltatoric conduction 
requires a much higher ATP consumption by the Na
+/K
+-
ATPase to maintain the excitability of the axolemma as 
compared to myelinated fibers [46]. An increased histo-
chemical and immunohistochemical staining for the ETC 
enzyme cytochrom c oxidase (COX) had been observed 
within the optic nerve head as compared to the retrobulbar 
axon section within the optic nerve [47]. According to such 
staines, mitochondria (COX activity) seemed to be concen-
trated around the sites of major energy demand, as evidenced 
by simultaneous staining for voltage sensitive sodium chan-
nels [48, 49]. The unmyelinated state of the first axon section 
may thus contribute to an enhanced susceptibility of RGCs 
towards an OXPHOS decline. The important role of this first 
axon section for the process of neurodegeneration is nicely 
supported by the regional increase of RNFL thickness, ob-
served early during desease development [50].  
4.1. Possible Role of the Distribution of Mitochondria 
within the Axon 
  The interpretation of the gradient of mitochondrial con-
tent between the intra- and retrobulbar axon sections [47, 51-
53] as a prerequisite of normal axon function has been the 
starting point for the hypothesis that any disturbance of this 
gradient may cause optic neuropathies [54].  
  When the axons leave the eye by a small opening in the 
sclera, they have to pass the lamina cribrosa, a perforated 
collagen plate. It had long been suggested that mechanical 
compression at this point restricts axoplasmic flow, leading 
to an accumulation of mitochondria in the prelaminar axon 
sections [33, 51, 52]. Small scleral openings had even been 
discussed as factors favouring optic neuropathies [55], al-
though no change in axon diameter had been observed at the 
lamina cribrosa [52].  
  In the light of more recent histochemical and immunohis-
tochemical findings, regarding the concentration of mito-
chondria at the sites of major OXPHOS demand, this hy-
pothesis was replaced by its opposite: the physiological need 
for the observed mitochondrial density gradient [48, 53]. 
Histochemical stains confirmed the abrupt occurrence of 
myelin sheets in the postlaminar portion of the axons [48]. 
COX activity was not detactable in these sections, while it 
was high in the pre- and intralaminar regions. The results for 
COX activity were confirmed using antibodies directed 
against COX subnunits I and IV. This abrupt gradient in the 
distribution of COX subunits and enzyme activity was ac-
companied by an according gradient in the immunohsto-
chemical staining for CNS-associated subtypes of voltage-
gated sodium channels [48]. This coincidence indicates the 
physiological relevance of enhanced mitochondrial OX-
PHOS capacity near sites of the axolemma, where depolari-
zation and subsequent ATP-consuming re-polarization are 
most required during nerve conduction. Precautions were 
taken to exclude the objection that the antibodies or secon-
dary immuno-reagents may have a reduced access to axonal 
proteins in the myelin-covered areas. For this purpose, neu-
rofilament immustaining was performed, which exhibited a 
strong signal along all portions of the axons under investiga-
tion. Such results can thus be interpreted in terms of a 
physiological need to trap mitochondria within those regions, 
which are unable of saltatoric conduction, instead of distrib-
uting mitochondria all along the axon with a homogeneous 
density. In rabbit eyes, where myelination starts at a more 
proximal site, enhanced mitochindrial activity is concomi-
tantly shifted to this anatomical site. This view is further 
supported by the inverse relation between mitochondrial 
density and myelination along the optic nerve [47, 53].  
  Since axonal transport itself requires ATP, the main-
tainance of this gradient may be affected rather early by 
OXPHOS-relevant mutations. Inhibited axonal transport may 
thus contribute to a critical local energy deprivation at the 
sites, where most ATP is needed. Moreover, a reduced motil-
ity of mitochondria is expected to inhibit the dynamics of 
mitochondrial fission and fusion, which is necessary to ex-
change mitochondrial contents among these organelles and 
to avoid critical loss of components, including mtDNA. An 
exchange of components (mtDNA, RNA, soluble proteins, 
small molecules) between migrating mitochondria within the 
axon is thought to be necessary for the maintainance of a 
pool of functional mitochondria. This exchange may par-
tially take place during short touches between the moving 
organelles, a mechanism designated ‘kiss and run’ [56].  
4.2. Clues from OPA-1 Mutations 
  In some optic neuropathies with RGC loss, disturbed 
axonal flow and mitochondrial interaction have been dis-
cussed to participate in the pathophysiology. One of them, 
dominant optic atrophy (DOA) can be caused by mutations 
of the OPA-1 gene, coding for a dynamin-related GTPase, 
which is essential for structural features of the inner mito-
chondrial membrane (christae) and is required to maintain 
the ability of mitochondria to fuse with each other. While 
outer membrane fusion does not require OPA-1 in mammal-
ian cells, a transient or complete mitochondrial fusion in-
volving the inner membrane, and allowing intermitochon-
drial exchange of constituents, depends on OPA-1 [57]. Si-
lencing of OPA-1 in HeLa cells resulted in a disorganized 
structure of the inner mitochondrial membrane, disturbed 
christae and fragmentation of the mitochondrial network [58-
60], thus supporting the role of OPA-1 as a pro-fusion pro-
tein. The protein is further required for the interaction be-
tween mitochondria and cytoskeleton [61]. The view that a 
disturbed mitochondrial distribution along the axon, together 
with a disturbed intermitochondrial exchange may be an im-
portant cause of axonal degeneration, is further supported by 
studies of paraplegin-deficient mice [62]. Mutations in the 
gene (SPG7), encoding this protein, underlie a form of he-
reditary spastic paraplegia, which can include optic neuropa-
thy. An impairment of axonal flow was demonstrated in 
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  Also LHON mutations may favour a disturbed spatial 
distribution of mitochondria, which in turn may enhance 
bioenergetic decline at the sites of highest energy demand 
[63]. Some histopathologic features of LHON are compatible 
with disturbed axonal flow, such as clumps of mitochondria 
in the retrolaminar sections of remaining axons, accumula-
tion of debris or microtubule depletion [63-65]. 
4.3. Glutamate Toxicity 
  One pathophysiologic hypothesis ascribes an important 
role in LHON to astroglial components of the neural retina. 
Having in mind the high mutational load observed in all in-
vestgated tissues, an indirect impact of a disturbed function 
of astroglial cells as metabolic supportes and protectors of 
RGCs appears to be possible. Complex I dysfunction in 
Müller glial cells was discussed to hamper the removal of 
glutamate from the neural retina, thus favouring glutamate 
excitotoxicity, which represents a major theme in neurode-
generative disorders. Müller glial cells are major glutamate 
sinks and their ability to pump glutamate largely, but not 
exclusively, relies on the activity of the excitatory amino 
acid transporter 1 (EAAT-1), designated glutamate aspartate 
transporter (GLAST) in rats and mice [66]. It has long been 
known that chronic low-dose glutamate administration into 
the vitreous is toxic to rat RGCs. Periodic glutamate injec-
tions into rat eyes, which increased the intravitreal glutamate 
concentration about 4-fold, were found to kill more than 
40% of RGCs within three months [67]. EAAT-1 had been 
implicated in excitotoxicity within the retina [68]. Using the 
143B.TK
- cybrid model, two cell clones for each of the mu-
tations at np3460, np11778 or np14484 of the mtDNA were 
compared to controls with respect to expression and activity 
of EAAT-1. It had been previously established that this pro-
tein is the main glutamate transporter in osteosarcoma-
derived cybrids. While expression was not affected by 
LHON mutations, transport activity was strongly decreased 
[69], a feature which was correlated with the level of ROS-
production in these cybrids, but not with their ATP content. 
Redox-sensitive sulfhydryl residues are known to exist in the 
EAAT-1 transporter, which can form disulfide bonds, 
thereby down-regulating transpor activity [70]. This mecha-
nism potentially links retinal excitotoxicity to oxidative 
stress induced by LHON mutations in Müller cells. The hy-
pothesis was supported by the observation that the antioxi-
dants Trolox and decylubiquinone could partially restore 
glutamate transport in LHON cybrids carrying the G3460A 
mutation [71]. The same report further supported an in-
volvement of complex I deficiency in EAAT-1 dysfunction 
by demonstrating a reduced glutamate transport of control 
cybrids treated with the complex I inhibitor rotenone. In ad-
dition, partial complex I inhibition of primary rat retinal cul-
tures by titration with rotenone, perturbed sodium-dependent 
glutamate transport [72], coincident with enhanced ROS 
production. However, the impact of EAAT-1/GLAST to 
mediate retinal glutamate toxicity remains questionable. 
Homozygeous GLAST knockout mice had normal retinae 
and other transporters were shown to participate in glutamate 
removal [73]. On the other hand, redox-sensitive thiol 
groups, regulating transport activity, were described in sev-
eral glutamate transporters [70], which may theoretically be 
targets of oxidative stress.  
5. INSIGHTS INTO THE PATHOMECHANISM FROM 
NON-CYBRID STUDIES  
5.1. Phosphorous MRS Reveals Altered Energy Metabo-
lism in Non-Retinal Tissues 
  While cybrid studies of the energy metabolism were af-
fected by the above mentioned constraints, a dysfunction of 
complex I at the level of enzyme activity had not been found 
consistently for all three common LHON mutations in pa-
tient tissues available for analysis. To assure a participation 
of energetic failure in the pathomechanism, the assessment 
of patient tissues with another, independent method was re-
quired to demonstrate a reduced phosporylation potential 
(PP) and a reduced energy reserve. 
31P- phosphorous mag-
netic resonance spectroscopy (
31P-MRS), a non-invasive 
spectroscopic technique, allows the relative quantification of 
the various phosphate-containing small molecules, which 
contribute to the PP, i.e. to the ability of cells to drive ATP-
consuming biochemical reactions. Moreover, changes of the 
energy reserve, available to re-phosphorylate ADP, are re-
flected by peaks for creatinin phosphate (CrP). Several stud-
ies during the 1990s consistently observed a decline of these 
parameters in LHON patients or mutation carriers 
(G11778A) in brain [74, 75] and skeletal muscle [74-76]. 
These results correspond well with the observed decline of 
the energy-conserving functions of ND4-mutants in the cy-
brid model, despite the lack of major changes in complex I 
enzyme activity.  
  A more recent study described a significant decrease of 
CrP and a corresponding increase of ADP for the G3460A 
mutation, but solely in occipital lobe tissue of the brain [77], 
not in skeletal muscle. Similar shifts of both parameters were 
not restricted to the index patient, but occurred also in two 
unaffected twin sisters The relative shifts of the 
31P-MRS-
peaks of the various phosphorous compounds per se can 
identify a disturbed energy metabolism. In addition, a quanti-
tative estimation of PP according to the formula PP = [ATP] 
/ ([ADP] x [Pi]) can be performed. For this purpose, an ATP-
concentration around 3 mM was assumed and used to cali-
brate the peaks. The calculated PP was strongly reduced in 
the occipital lobes of the index patient and his unaffected 
sisters [77]. 
  Taken together, these results strongly support an im-
paired energy conserving function of complex I in neural 
tissues of LHON patients and mutation carriers. The results 
support a role of decreased OXPHOS in the pathomecha-
nism. Remarkably, these studies suggest that the basic bio-
chemical defect occurs also in non-retinal neural tissues, 
which offers an explanation for the more complex LHON 
phenotypes, which are occasionally observed.  
5.2. Mitochondrial Dysfunction of RGCs Alone is Suffi-
cient to Elicit LHON 
  Despite the more wide-spread tissue distribution of the 
biochemical defects, recent experiments with AAV-mediated 
in vivo gene transfer of the mutant human ND4-subunit into 
murine RGCs clearly demonstrated that the expression of the 
biochemical defect in RGCs is sufficient to elicit loss of 
these neurons and optic nerve degeneration [78].  LHON: Mitochondrial Mutations and More  Current Genomics, 2011, Vol. 12, No. 1    51 
  Experiments of this type were thus not only a prerequisite 
to establish basic transfection techniques for an upcoming 
gene therapy approach (see paragraph 7). At the same time 
they provided the first direct in vivo evidence for the hy-
pothesis that severe complex I dysfunction solely in RGCs is 
sufficient to elicit the disease, while concomitant expression 
of the defect in other neural or glial cell types of the CNS is 
not required.  
  Since the retinal gene transfer experiments did not allow 
in-depth biochemical analysis, it may be argued that RGC 
death by overexpression of a mutant ND4-subunit may par-
tially rely on unspecific toxicity due to a massive overload of 
cells with a foreign protein. However, Qi and colleagues [78] 
not only observed the expression of their transgenic ND4 
polypeptide by Western blotting of retinal tissues, they also 
verified the import of the tagged polypeptide into RGC mi-
tochondria by immunogold-labeling and demonstrated a dis-
tribution of the tagged mitochondria along the optic nerve. 
The authors also verified the incorporation of the human 
ND4-polypeptide into the mouse complex I by immunopre-
cipitation [78]. Finally, the objection of unspecific toxicity 
can largely be rejected, considering the successful abolish-
ment of induced RGC loss by subsequent gene transfer of 
human wild-type ND4, as demonstrated by a recent study in 
rats [79].  
6. ROLE OF MODIFIER GENES  
  Since all the above mentioned pathomechanisms (sum-
marized in Fig. 4) do neither explain incomplete penetrance, 
nor gender bias, additional genetic and environmental factors 
have been considered. Mitochondrial haplogroups have been 
discussed to play a role for the probability of disease out-
break in mutation carriers. A haplogroup represents a branch 
of the evolutionary tree of human mtDNA, which is charac-
terized by a certain set of mtDNA polymorphisms. 
Haplogroup J was found to be over-represented in LHON 
pedigrees with the T14484C and G11778A mutations, sug-
gesting a synergistic role of this haplogroup [80]. It may be 
hypothesized that a certain haplogroup more frequently car-
ries additional polymorphisms in mitochondrial genes, which 
are associated with a lower OXPHOS capacity and favour 
LHON expression. For example, sub-haplogroups J2b and 
Jc1 were associated with higher penetrance of the G11778A 
and T14484C mutations, respectively. Both sub-haplogroups 
differ by one amino acid, encoded by the cytochrome b gene 
of the mtDNA (MTCYB), which may influence the function 
of ETC complex III.  
  It is well known that the frequency of some haplogroups 
differs between ethnic groups. The importance of a given 
haplogroup-association may thus be restricted to certain 
geographic regions, as already stated by Hudson and col-
leagues [81].  
  Huge efforts have been undertaken in the last years to 
identify LHON susceptibility alleles in the nuclear genome. 
An X-chromsomal locus was in the focus due to the marked 
over-representation of males among the diseased carriers of 
primary mutations. An X-linked susceptibility locus had first 
been ascribed to the microsatellite DXS7 in Finnish pedi-
grees [82]. Several other X-linked loci were identified later, 
suggesting heterogeneity between ethnic groups [83-85], just 
as assumed for the role of mitochondrial haplogroups. In the 
year 2010, a genome-wide linkage analysis with 400 micro-
satellite markers in LHON pedigrees from Thailand revealed 
a moderate association of LHON with markers not only on 
the X-chromosome, but also on chromosomes 1, 3, 12, 13 
and 18 [86]. The region between 3q26.2 and 3q28 was most 
suggestive. Among other mitochondia-associated genes, it 
carries the gene OPA-1 and the gene PARL ( presenelin-
associated rhomboid like). The protease PARL is thought to 
cooperate with OPA-1 in influencing apoptosis. In the Thai 
pedigrees, a role of PARL as a susceptibility gene was fur-
ther supported by the observation, that two intrageneous 
SNPs (single nucleotide polymorphisms) were LHON-
associated. However, an independent study of Chinese 
LHON patients could not find any difference in the frequen-
cies if these SNPs (alleles or genotypes) between LHON 
patients with a known primary mutation, suspected LHON 
patients without primary mutation and controls without optic 
neuropathy [87]. These conflicting results again support the 
notion that susceptibility loci determined in a geographically 
limited set of LHON pedigrees may bear the risk of specific-
ity for a certain ethnic background. It may be considered that 
a set of susceptibility genes with heterogeneous allele distri-
butions among ethnic groups may be involved in the disease.  
  Many ‘environmental’ factors, such as smoking, alcohol 
abuse, the antibiotic ethambutol and environmental noxes 
had been discussed to play a role in LHON. Moreover, an 
impact of malnutrition and noxes was supported by the Cu-
ban epidemic outbreak of a LHON-like optic neuropathy 
without any underlying mtDNA mutations [88]. However, 
only heavy smoking could be statistically verified to enhance 
the risk of mutation carriers to develop the disease [89].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Schematic drawing showing the major pathophysiologic 
mechanisms discussed for primary LHON mutations to occur in 
retinal ganglion cells (RGC) or Müller glial cells. PT = permeabil-
ity transition, EAAT-1 = excitatory amino acid transporter 1, ROS 
= reactive oxygen species.  
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7. FUTURE PERSPECTIVES OF LHON TREATMENT  
  Despite the incomplete knowledge of pathomechanisms, 
there is some hope for pharmacological and genetic interven-
tion, which may slow down disease progression.  
  Primary LHON mutations are single base substitutions, 
which require a high mutational load to cause the disease. 
Moreover, the degenerating retinal cell type (RGC) is ex-
posed to the vitreous and thus easily accessible for plasmid 
or viral vectors injected into this compartment of the eye. 
These are prerequisites, which favoured the development of 
a local gene therapy approach, aimed to restore heteroplasmy 
by delivery of a corresponding wild-type subunit of complex 
I. On the other hand, several obstacles had to be overcome 
on this route. In living cells, mtDNA-encoded ND-subunits 
are transcribed and translated within the mitochondrial ma-
trix and do not possess mitochondrial import sequences. 
Since efficient gene transfer into mitochondria is not possi-
ble in vivo, vectors had to be constructed for so called ‘allo-
topic expression’. The wtND-subunit of interest was cloned 
into vectors, which allowed regular cytoplasmic translation 
of the polypeptide and import into mitochondria by fusion to 
a suitable targeting sequence. To reach this goal, the cloned 
coding sequence of the ND-subunit had to be adapted to the 
‘universal genetic code’, which slightly differs from the mi-
tochondrial code. This was achieved by in vitro mutagenesis. 
Moreover, it was not clear in the beginning, if the allotopi-
cally expressed human subunit is correctly integrated into 
complex I during its assembly.  
  A successful reversal of the ATP decline in G11778A 
cybrids was reported by allotopic wtND4 expression using 
an adeno-associated viral vector (AAV) [90]. Injection of the 
same vector, but carrying the mutant ND4 gene, into the vit-
reous of mouse eyes demonstrated for the first time that the 
route of gene transfer was applicable in vivo. Moreover, it 
suggested incorporation of the transgenic subunit into com-
plex I, since optic neuropathy occurred [78]. An even more 
powerful proof-of-principle for the technique of gene deliv-
ery and for its therapeutic potential was recently provided by 
Ellouze and colleagues. The authors reported that RGC loss 
in rats cannot only be elicited by delivery of a mutant ND4 
gene into rat eyes, but also be prevented by subsequent trans-
fer of wtND4 two weeks later [79]. These developments cre-
ated some hope regarding a possible gene therapy, which 
restores complex I function in patients with the most com-
mon ND4 defect [91].  
  Currently, pharmacological interventions with antioxi-
dants represent a faster, and relatively safe route for develop-
ing LHON treatments, as evaluated in an ongoing double-
blind, placebo-controlled clinical trial with the ubiquinone-
derivative idebenone. However, these treatments are de-
signed to attenuate a probable biochemical consequence of 
LHON mutations and not to cure the primary defect. The 
results of clinical trials will show, which impact idebenone 
may have for a better clinical outcome of patients. In all 
types of therapeutic interventions, an early start of treatment 
will be crucial, as will be the further improvement of meth-
ods, allowing early identification of mutation carriers at risk. 
Molecular genetic approaches will not be of major impor-
tance for the latter purpose, as long as no modifier alleles can 
be identified with an impact going beyond a limited set of 
regional pedigrees.  
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